Results from Merck ’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the publication of results fromC-EDGE
CO-STAR.C-EDGE CO-STAR is a Phase 3 trial evaluating the
use of ZEPATIER ™ (elbasvir and grazoprevir) 50mg/100mg tablets in
patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6
infection receiving opioid agonist therapy (OAT) (methadone and
buprenorphine), commonly used to treat opioid addiction.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK Annals of Internal Medicine MSD ZEPATIER Source Type: news
More News: Addiction | Drugs & Pharmacology | Hepatitis | Hepatitis C | Internal Medicine | Merck | Methadone | Study